Vivos Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$17M
Cost of Revenue
$7M
Gross Profit
$11M
R&D
$100K
D&A
$1M
Operating Income
$-20M
EBITDA
$-19M
Interest Expense
$1M
Interest Income
—
Other Income/Expense
$64K
Pretax Income
$-21M
Net Income
$-21M
Gross Margin
60.4%
Operating Margin
-114.1%
Net Margin
-121.4%
Deferred Tax Assets
$1M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$26M
NOL Carryforwards
$105M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
—
ETR State + Local (pp)
-3.0%
Operating Lease Cost
$1M
Revenue YoY Variation
16.0%
Income YoY Variation
-78.1%